Next Article in Journal
Role of Factor H and Related Proteins in Regulating Complement Activation in the Macula, and Relevance to Age-Related Macular Degeneration
Next Article in Special Issue
Pediatric AML: From Biology to Clinical Management
Previous Article in Journal
The Insulin-Like Growth Factor System in Obesity, Insulin Resistance and Type 2 Diabetes Mellitus
Previous Article in Special Issue
Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
Open AccessReview

Clinical Results of Hypomethylating Agents in AML Treatment

Department of Hematology, Radboud University Medical Center, PO Box 9191, 6500 HB Nijmegen, The Netherlands
Department of Medicine, University of Freiburg Medical Center, D-79106, Freiburg, Germany
Department of Hematology, Haga Hospital, 2545 CH, The Hague, The Netherlands
Author to whom correspondence should be addressed.
Academic Editor: Celalettin Ustun
J. Clin. Med. 2015, 4(1), 1-17;
Received: 18 September 2014 / Accepted: 2 December 2014 / Published: 25 December 2014
(This article belongs to the Special Issue AML in the Molecular Age: From Biology to Clinical Management)
Epigenetic changes play an important role in the development of acute myeloid leukemia (AML). Unlike gene mutations, epigenetic changes are potentially reversible, which makes them attractive for therapeutic intervention. Agents that affect epigenetics are the DNA methyltransferase inhibitors, azacitidine and decitabine. Because of their relatively mild side effects, azacitidine and decitabine are particularly feasible for the treatment of older patients and patients with co-morbidities. Both drugs have remarkable activity against AML blasts with unfavorable cytogenetic characteristics. Recent phase 3 trials have shown the superiority of azacitidine and decitabine compared with conventional care for older AML patients (not eligible for intensive treatment). Results of treatment with modifications of the standard azacitidine (seven days 75 mg/m2 SC; every four weeks) and decitabine (five days 20 mg/m2 IV; every four weeks) schedules have been reported. Particularly, the results of the 10-day decitabine schedule are promising, revealing complete remission (CR) rates around 45% (CR + CRi (i.e., CR with incomplete blood count recovery) around 64%) almost comparable with intensive chemotherapy. Application of hypomethylating agents to control AML at the cost of minimal toxicity is a very promising strategy to “bridge” older patients with co-morbidities to the potential curative treatment of allogeneic hematopoietic cell transplantation. In this article, we discuss the role of DNA methyltransferase inhibitors in AML. View Full-Text
Keywords: AML; azacitidine; decitabine; hypomethylating agents; elderly; epigenetics AML; azacitidine; decitabine; hypomethylating agents; elderly; epigenetics
Show Figures

Figure 1

MDPI and ACS Style

Cruijsen, M.; Lübbert, M.; Wijermans, P.; Huls, G. Clinical Results of Hypomethylating Agents in AML Treatment. J. Clin. Med. 2015, 4, 1-17.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop